Hiroyuki Mano

TL;DR: It is shown that a small inversion within chromosome 2p results in the formation of a fusion gene comprising portions of the echinoderm microtubule-associated protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC) cells.

TL;DR: A multivariate analysis of 1,116 adenocarcinomas containing 71 kinase-fusion–positive adenokcinomas identified four independent factors that are indicators of poor prognosis: age ≥50 years, male sex, high pathological stage and negative kinase -fusion status.

TL;DR: The discovery of two secondary mutations within the kinase domain of EML4-ALK in tumor cells isolated from a patient during the relapse phase of treatment with an ALK inhibitor are reported.

TL;DR: It is demonstrated that downregulation of ALK through RNA interference suppresses proliferation of neuroblastoma cells harbouring mutated ALK, and that ALK-specific kinase inhibitors might improve its clinical outcome.

TL;DR: An intercalated antibody-enhanced polymer (iAEP) method that incorporates an intercalating antibody between the primary antibody to ALK and the dextran polymer-based detection reagents should prove suitable for immunohistochemical screening of tumors positive for ALK or ALK fusion proteins among pathologic archives.